Vaccines and Correlates of Protection
Combating flu in a Combined Action Between Industry
and the Public Sector in Order to Secure Adequate and Fast Intervention
- EC contribution
- : € 3 749 685
- : 36 months
- Starting date
- : 01/02/2006
- : Public Health Programme
- : Pandemic influenza, public-private partnership, cross protection,
reassortants, adjuvants, vaccine efficacy, clinical network
- Project Number
- : 2005207
- : www.flusecure.eu
New or deliberately released viruses are a continuing serious health
threat for which no effective countermeasures are available. The main
problem is that no vaccine can be produced in advance as the exact nature
of the virus is not known until the outbreak starts. Pandemic influenza
is now felt to be the major health threat, especially with respect to
the difficulties in effective preparedness planning. As pandemic influenza
is a cross-border problem, it needs a cross-border solution. This requires
that European industry and public health authorities collaborate to gain
control over it. As an overall objective this project aims to 'enable
the manufacture of the most effective pandemic vaccine in the shortest
possible time in sufficient quantity for the EU population, by setting
up a European network of public health institutes as the public sector
input for a public-private partnership'.
Pandemic influenza currently is the greatest infectious diseases threat
to public health. The establishment of a public consortium is essential
for assisting manufacturers in the timely production and testing of influenza
vaccines for the European population.[+] Read More
- To enable the production of the most effective pandemic vaccine in
the shortest possible time in sufficient quantity for the EU population.
- To establish a European network of public health institutes for a
public-private partnership on European pandemic influenza vaccines.
- To enhance vaccine preparedness in the case of an influenza pandemic.
- The establishment of a process of continuous dialogue with vaccine
manufacturers to ensure that the assets of the public and private sectors
are used to the best advantage to increase the availability of vaccines
to the European population.
- A decrease in the lead time of vaccine production by establishment
of a library of safety-tested reference influenza strains available
- An improvement in the efficacy of pandemic influenza vaccines in terms
of formulation, adjuvants and dosing regimens.
- Quantification of vaccine efficacy by establishment of cross protection
and advanced correlates of protection.
- Evaluation of the pandemic vaccines in use by providing a strategy
to set up a multi-centre clinical trial network and post marketing surveillance.
This will assist industry in producing efficacy and surveillance data
in the event that vaccines are produced and utilised under the mock-dossier
- Creation of a library of tested reassortants and reagents which will
be available for direct vaccine production.
- Optimised vaccine formulation for influenza vaccines in terms of formulation,
adjuvants and dosing regimen.
- Quantification efficacy assays for cross protection and advanced correlates
- Multi-centre clinical trial network and post marketing surveillance
network available for pandemic vaccine studies in Europe.
Provides a platform for public (governments and academia) and private
(vaccine manufacturers) studies on pandemic vaccines.
Prof. Dr B A M van der Zeijst
Dr E D L Schmidt
Nederlands Vaccin Instituut
Antonie van Leeuwenhoeklaan 11
P.O. Box 457
3720 AL Bilthoven